Evaulating The Durability of Response in New Biologics for Psoriasis
Abstract
Psoriasis (PsO) is a chronic inflammatory disease with a prevalence estimated at 1–3%. Biologic therapies have revolutionized the treatment of PsO, with subsequent generations of biologics showing ever‑increasing efficacy. There are currently 12 originator biologics approved in Canada. In addition, numerous biosimilars have been approved. Phase 3 trials have reported efficacy ranging from PASI 75 rates of 49% from some of the earliest biologics still available, such as etanercept, up to PASI 90 response rates of 85% for the most recent biologics such as bimekizumab. With the number needed to treat to obtain a PASI 90 response approaching one with bimekizumab, it is important to ask how durable the response will be in order to avoid having to switch biologics after an initial response. This article will review my process for evaluating the durability of response of a new agent.
References
Koo J. Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin. 1996;14:485-496.
Gelfand JM, Weinstein R, Porter SB, et al. Prevalence and treatment of psoriasis in the United Kingdom: a populationbased study. Arch Dermatol 2005;141:1537-1541.
Papp KA, Tyring S, Lahfa M, et al, Etanercept Psoriasis Study Group. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol. 2005 Jun 1;152(6):1304-1312.
Reich K, Papp KA, Blauvelt A, et al. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. Lancet. 2021 Feb 6;397(10273):487-498.
Griffiths CE, Papp KA, Song M, et al. Continuous treatment with guselkumab maintains clinical responses through 4 years in patients with moderate-to-severe psoriasis: results from VOYAGE 1. J Dermatolog Treat. 2022 Feb 17;33(2):848-856.
Papp KA, Lebwohl MG, Puig L. 33270 Long-term efficacy and safety of risankizumab (RZB) for the treatment of moderate to-severe plaque psoriasis: Interim analysis of results from the LIMMitless open-label extension trial beyond 4 years of follow-up. J Am Acad Dermatol. 2022 Sep 1;87(3):AB77.
Papp K, Reich K, Blauvelt A, et al. Clinical efficacy or tildrakizumab in patients with chronic plaque psoriasis over 2 years of treatment: results from long-term extensions to 2 phase 3 clinical studies. SKIN. 2018 Feb 23;2.
Blauvelt A, Lebwohl MG, Mabuchi T, et al. Long-term efficacy and safety of ixekizumab: A 5-year analysis of the UNCOVER-3 randomized controlled trial. J Am Acad Dermatol. 2021 Aug 1;85(2):360-368.
Langley RG, Sofen H, Dei-Cas I, et al. Secukinumab longterm efficacy and safety in psoriasis through to year 5 of treatment: results of a randomized extension of the phase III ERASURE and FIXTURE trials. Br J Dermatol. 2023 Feb 1;188(2):198-207.
Puig L, Lebwohl M, Bachelez H, et al. Long-term efficacy and safety of brodalumab in the treatment of psoriasis: 120-week results from the randomized, double-blind, placebo-and active comparator–controlled phase 3 AMAGINE-2 trial. J Am Acad Dermatol. 2020 Feb 1;82(2):352-359.
Thaçi D, Vender R, de Rie MA, et al. Safety and efficacy of bimekizumab through 2 years in patients with moderateto-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial. Br J Dermatol. 2023 Jan 23;188(1):22-31.
Strober B, Tada Y, Mrowietz U, et al. Bimekizumab maintenance of response through 3 years in patients with moderate-to-severe plaque psoriasis: results from the BE BRIGHT open-label extension trial. Br J Dermatol. 2023 Jun;188(6):749-759.
Egeberg A, Bryld LE, Skov L. Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2019 Jul 1;81(1):173-178.
